Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Hanger Orthopedic Group (HGR)
Financials 
Technical Analysis 0
TOP PICK
PAST TOP PICK
(Top Pick Dec 15/10, Down 12.13%) Their margins were weak in the third quarter. Medicaid was not covering in certain states. 11 times earnings now and seemingly back on track. Prospects look good going forward.
Gordon ReidOwned
Consumer Products
PAST TOP PICK
(A Top Pick 15/10. Down 22.51%.) Expects over $1.60 in earnings this year and trades at 10X earnings.
Gordon ReidOwned
Consumer Products
PAST TOP PICK
Dec 15,2010 Recommended at $21.10 down 29.05%
Industry is down. Still thinks has good prospects, trading at less then 10X for what is expected for 2011.
Gordon ReidOwned
Consumer Products
TOP PICK
Orthopedics distribution and patient care services. Most revenues come from insurance or Medicare so are pretty much guaranteed to be paid. Growing well.
Gordon ReidOwned
Consumer Products
Showing 1 to 5 of 5 entries
- «
- ‹
- 1
- ›
- »
Hanger Orthopedic Group (HGR) Frequently Asked Questions
What is Hanger Orthopedic Group stock symbol?
Hanger Orthopedic Group is a OTC stock, trading under the symbol HGR (previously HGR-N on Stockchase) on the undefined (undefined). It is usually referred to as or HGR
Is Hanger Orthopedic Group a buy or a sell?
In the last year, no analyst issued a Buy, Sell, or Hold rating on HGR (previously HGR-N on Stockchase) on Stockchase. Read the latest expert commentary for Hanger Orthopedic Group.
Is Hanger Orthopedic Group a good investment or a top pick?
Hanger Orthopedic Group was recommended as a Top Pick by Gordon Reid on 2010-12-15. Read the latest stock experts ratings for Hanger Orthopedic Group.
Why is Hanger Orthopedic Group stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Hanger Orthopedic Group.
Is Hanger Orthopedic Group worth watching?
Hanger Orthopedic Group is covered by Stockchase experts and is worth watching.
Market leader in orthotics and prosthetic space. Medicare slowed down their billing cycle. Now 95% of questioned transactions have gone through. 10 times market share of nearest competitor. Solid growth (organic). It is currently below the radar. He has owned it for years and recently bought more.